S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Halozyme TherapeuticsIovance BiotherapeuticsAllogene TherapeuticsMomenta PharmaceuticalsCrispr Therapeutics
SymbolNASDAQ:HALONASDAQ:IOVANASDAQ:ALLONASDAQ:MNTANASDAQ:CRSP
Price Information
Current Price$16.25$29.06$18.89$24.19$39.38
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$25.33$34.62$33.11$37.25$74.42
% Upside from Price Target55.90% upside19.12% upside75.28% upside53.99% upside88.99% upside
Trade Information
Market Cap$2.25 billion$3.63 billion$2.30 billion$2.89 billion$2.34 billion
Beta1.711.341.081.562.53
Average Volume1,864,7281,875,387662,0171,305,8771,060,980
Sales & Book Value
Annual Revenue$195.99 millionN/AN/A$23.87 million$289.59 million
Price / Sales11.45N/AN/A118.858.27
CashflowN/AN/AN/AN/A$1.33 per share
Price / CashN/AN/AN/AN/A29.68
Book Value$0.63 per share$2.37 per share$5.16 per share$4.59 per share$17.02 per share
Price / Book25.79N/AN/A5.272.31
Profitability
Net Income$-72,240,000.00$-197,560,000.00$-184,590,000.00$-290,050,000.00$66.86 million
EPS($0.50)($1.59)($1.83)($3.03)$1.17
Trailing P/E RatioN/AN/AN/AN/A40.60
Forward P/E Ratio11.44N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-36.86%N/AN/A-1,215.25%23.09%
Return on Equity (ROE)-33.71%-53.17%-28.56%-82.12%11.74%
Return on Assets (ROA)-16.20%-48.25%-25.49%-58.59%9.62%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio4.17%0.01%0.08%N/AN/A
Current Ratio6.35%8.10%16.46%5.08%17.29%
Quick Ratio6.00%8.10%16.46%5.08%17.29%
Ownership Information
Institutional Ownership Percentage91.73%99.05%57.34%97.03%52.02%
Insider Ownership Percentage2.60%9.30%36.50%3.40%21.40%
Miscellaneous
Employees28188122131188
Shares Outstanding138.07 million126.50 million124.91 million117.28 million60.85 million
Next Earnings Date5/5/2020 (Estimated)5/5/2020 (Estimated)5/5/2020 (Estimated)5/7/2020 (Estimated)5/4/2020 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel